Cidara Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Cidara Therapeutics
CDTX Stock  USD 19.59  0.90  4.82%   
Cidara Therapeutics financial statements provide useful quarterly and yearly information to potential Cidara Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Cidara Therapeutics financial statements helps investors assess Cidara Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Cidara Therapeutics' valuation are summarized below:
Gross Profit
-11.2 M
Profit Margin
(2.11)
Market Capitalization
131.7 M
Enterprise Value Revenue
0.185
Revenue
53.9 M
We have found one hundred twenty available fundamental signals for Cidara Therapeutics, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Cidara Therapeutics prevailing market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 116.9 M in 2024. Enterprise Value is likely to rise to about 54.5 M in 2024

Cidara Therapeutics Total Revenue

67.1 Million

Check Cidara Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cidara Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 210.4 K, Selling General Administrative of 14 M or Other Operating Expenses of 63.2 M, as well as many indicators such as Price To Sales Ratio of 1.03, Dividend Yield of 0.0 or Days Sales Outstanding of 111. Cidara financial statements analysis is a perfect complement when working with Cidara Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Cidara Therapeutics Correlation against competitors.
For more information on how to buy Cidara Stock please use our How to Invest in Cidara Therapeutics guide.

Cidara Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets71.9 M67 M52.8 M
Slightly volatile
Short and Long Term Debt Total5.5 M4.9 M6.1 M
Pretty Stable
Other Current Liabilities18.8 M17.9 M6.7 M
Slightly volatile
Total Current Liabilities70.8 M67.4 M21.4 M
Slightly volatile
Accounts Payable2.6 M3.8 M1.9 M
Slightly volatile
Cash44.5 M35.8 M43.8 M
Slightly volatile
Non Current Assets Total6.5 M6.2 M2.2 M
Slightly volatile
Non Currrent Assets Other767 K1 M563.1 K
Slightly volatile
Other Assets905.3 K1.2 M710.1 K
Slightly volatile
Cash And Short Term Investments44.5 M35.8 M43.8 M
Slightly volatile
Common Stock Shares Outstanding4.6 M4.4 M1.5 M
Slightly volatile
Liabilities And Stockholders Equity71.9 M67 M52.8 M
Slightly volatile
Non Current Liabilities Total8.5 M7.8 M6.5 M
Slightly volatile
Other Current Assets4.5 M2.7 M3.3 M
Slightly volatile
Other Stockholder Equity262.2 M433.2 M192.3 M
Slightly volatile
Total Liabilities79 M75.2 M27.5 M
Slightly volatile
Total Current Assets69.2 M60.9 M50.8 M
Slightly volatile
Other Liabilities22.2 M21.2 M8.2 M
Slightly volatile
Property Plant And Equipment Net5.4 M5.1 M1.8 M
Slightly volatile
Property Plant And Equipment Gross8.7 M8.3 M2.4 M
Slightly volatile
Common Stock9.4 K9 K3.5 K
Slightly volatile
Property Plant Equipment189.8 K199.8 K870.3 K
Pretty Stable
Common Stock Total Equity8.5 K8.1 K3.4 K
Slightly volatile
Capital Surpluse293.1 M464.7 M251.6 M
Slightly volatile
Non Current Liabilities Other24.8 M23.6 M6.8 M
Slightly volatile
Net Receivables17.1 M16.2 M4.3 M
Slightly volatile
Long Term Debt Total6.8 M6.5 M8.3 M
Slightly volatile
Short and Long Term Debt2.2 M2.3 M7.2 M
Slightly volatile
Short Term Debt5.1 M2.6 M7.6 M
Slightly volatile
Current Deferred Revenue15.4 M25.1 M10.2 M
Slightly volatile
Capital Stock6 K9 K4.2 K
Slightly volatile
Capital Lease Obligations2.5 M4.9 M2 M
Slightly volatile

Cidara Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative14 M18.3 M10.3 M
Slightly volatile
Other Operating Expenses63.2 M88.4 M46.5 M
Slightly volatile
Research Development49 M68.5 M36.1 M
Slightly volatile
Total Operating Expenses63 M86.9 M46.4 M
Slightly volatile
Non Recurring1.3 M1.4 M1.6 M
Slightly volatile
Preferred Stock And Other Adjustments2.4 M2.5 M7.3 M
Slightly volatile
Interest Income1 M2 M661.4 K
Pretty Stable

Cidara Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation3.9 M3.1 M2.8 M
Slightly volatile
Begin Period Cash Flow50.5 M32.7 M37 M
Slightly volatile
Other Non Cash Items1.3 M1.2 M384.5 K
Pretty Stable
End Period Cash Flow54 M35.8 M39.7 M
Slightly volatile
Change To Netincome3.9 M4.1 M3.2 M
Slightly volatile
Issuance Of Capital Stock25.4 M26 M14.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.031.08634.4086
Slightly volatile
Days Sales Outstanding11192.790741.0592
Slightly volatile
Stock Based Compensation To Revenue0.04550.04790.1996
Slightly volatile
EV To Sales0.570.60272.5345
Slightly volatile
Payables Turnover0.380.40382.8063
Pretty Stable
Sales General And Administrative To Revenue0.270.28690.6869
Slightly volatile
Research And Ddevelopement To Revenue1.021.07242.1709
Pretty Stable
Capex To Revenue0.00610.00790.0033
Slightly volatile
Cash Per Share7.788.184681.8038
Pretty Stable
Days Payables Outstanding1.3 K9041.9 K
Slightly volatile
Income Quality0.650.97820.7922
Very volatile
Current Ratio0.860.90273.8796
Pretty Stable
Receivables Turnover3.743.93361.4 K
Slightly volatile
Graham Number14.1414.8887270
Slightly volatile
Capex Per Share0.110.11558.2668
Slightly volatile
Average Receivables8.8 M9.9 M10.8 M
Slightly volatile
Revenue Per Share11.4714.61913.9299
Very volatile
Interest Debt Per Share0.280.297427.5786
Slightly volatile
Debt To Assets0.02120.02232.0292
Slightly volatile
Days Of Payables Outstanding1.3 K9041.9 K
Slightly volatile
Ebt Per Ebit1.110.91851.0621
Slightly volatile
Long Term Debt To Capitalization0.120.10764.7316
Slightly volatile
Quick Ratio0.770.81223.8867
Pretty Stable
Net Income Per E B T0.811.01970.9754
Pretty Stable
Cash Ratio0.50.53073.6885
Pretty Stable
Days Of Sales Outstanding11192.790741.0592
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.121.02251.0573
Slightly volatile
Fixed Asset Turnover15.5412.464413.6001
Slightly volatile
Debt Ratio0.02120.02232.0292
Slightly volatile
Price Sales Ratio1.031.08634.4086
Slightly volatile
Asset Turnover0.550.95340.4496
Slightly volatile

Cidara Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap116.9 M69.4 M137.1 M
Slightly volatile
Enterprise Value54.5 M38.5 M62.9 M
Slightly volatile

Cidara Fundamental Market Drivers

Forward Price Earnings5.7504
Cash And Short Term Investments35.8 M

Cidara Upcoming Events

28th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Cidara Therapeutics Financial Statements

Cidara Therapeutics investors use historical fundamental indicators, such as Cidara Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Cidara Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue25.1 M15.4 M
Total Revenue63.9 M67.1 M
Cost Of Revenue1.5 M1.4 M
Stock Based Compensation To Revenue 0.05  0.05 
Sales General And Administrative To Revenue 0.29  0.27 
Research And Ddevelopement To Revenue 1.07  1.02 
Capex To Revenue 0.01  0.01 
Revenue Per Share 14.62  11.47 
Ebit Per Revenue(0.38)(0.40)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
RSIRush Street Interactive
OKTAOkta Inc
BACBank of America

Additional Tools for Cidara Stock Analysis

When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY